ARTICLE | Company News

NICE backs Invokana for Type II diabetes

February 25, 2014 1:03 AM UTC

The U.K.'s NICE issued Invokana canagliflozin from Johnson & Johnson (NYSE:JNJ) in combination regimens for Type II diabetes. NICE recommended Invokana in combination with metformin and a sulfonylurea or insulin with or without other antidiabetic drugs. The committee recommended use of Invokana as a dual therapy in combination with metformin only in patients at significant risk for hypoglycemia or when a sulfonylurea is contraindicated or not tolerated. Comments on the draft guidance are due March 17. ...